FILE PHOTO: A logo of Sanofi is pictured during the company’s shareholders meeting in Paris, France, April 30, 2019. REUTERS/Benoit Tessier/File Photo
The deal will give Sanofi exclusive U.S. over-the-counter (OTC) rights to Tamiflu, which is used for the prevention and treatment of flu.
“This is a strategic and important transaction for us as we strive to continually bring innovations to the market,” said Alan Main, executive vice president of Sanofi’s consumer healthcare division, in a statement.
Reporting by Sudip Kar-Gupta; Editing by Subhranshu Sahu
View original article here Source